Premarket Movers | American Eagle Soars 24%; Credo Jumps 13%; Asana Gains 10%; Sanofi Falls 9%

Tiger Newspress
09/04

American Eagle Outfitters shares jumped 24% in premarket trading on Thursday.

American Eagle Outfitters forecast third-quarter comparable sales above expectations on Wednesday, signaling a demand boost in the fall season from its Sydney Sweeney and Travis Kelce partnerships.

Its shares surged as the company hailed the controversial "Great Jeans" campaign with actress Sydney Sweeney, which included a fall denim collection, as a success.

Credo Technology Group Holding Ltd reported better-than-expected earnings results on Wednesday afternoon. Its shares were up 13% in premarket trading on Thursday.

The company reported fiscal first-quarter adjusted earnings per share of 52 cents, compared to Wall Street’s consensus estimate of 36 cents, according to FactSet. Revenue came in at $223.1 million, or up 274% year-over-year, which was above analysts’ expectations of $190.6 million.

Credo’s outlook was also strong. For the current quarter, it forecast a sales range with $235 million at the midpoint versus the $201.9 million consensus analyst estimate.

Asana, Inc. shares rose 10% premarket after the company reported second-quarter EPS of $0.06, better than the analyst estimate of $0.05. Revenue for the quarter came in at $196.9M versus the consensus estimate of $193.04M.

Asana sees FY 2026 EPS of $0.23-$0.25 versus the analyst consensus of $0.23.

Asana sees FY 2026 revenue of $780.00M-$790.00M versus the analyst consensus of $782.00M.

Sanofi SA fell 9% in premarket trading on Thursday after the company said its amlitelimab experimental drug met all main goals in a late-stage clinical trial with eczema patients.

The French pharmaceutical company said Thursday that amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with eczema, also known as atopic dermatitis. The drug’s efficacy increased progressively throughout the treatment period, the company added.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10